4.3 Article

Temporal trends and current use of de novo belatacept in kidney transplant recipients in the United States

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Surgery

CMV high-risk status and posttransplant outcomes in kidney transplant recipients treated with belatacept

Geeta Karadkhele et al.

Summary: In CMV high-risk kidney transplant recipients, belatacept-based maintenance immunosuppression may increase the risk of primary CMV infection and prolong the course of viral replication. While patients treated with belatacept showed a trend towards lower graft survival, this conclusion was not statistically significant. Further studies are needed to confirm these findings and explore the relationship between belatacept treatment and CMV outcomes.

AMERICAN JOURNAL OF TRANSPLANTATION (2021)

Article Transplantation

Opportunistic infections after conversion to belatacept in kidney transplantation

Dominique Bertrand et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2020)

Article Medicine, General & Internal

Belatacept and Long-Term Outcomes in Kidney Transplantation

Flavio Vincenti et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Article Surgery

Summary of the US FDA Approval of Belatacept

P. Archdeacon et al.

AMERICAN JOURNAL OF TRANSPLANTATION (2012)